A Multi-center Retrospective Study of INO Treating B-ALL

Inclusion criteria

• Age between ≥16 and ≤80 years at screening, no gender restrictions
• Be diagnosed with B-ALL
• Appropirate organ function, meeting the following criteria:

• Aspartate aminotransferase (AST) ≤3 times the upper limit of normal (ULN);
• Alanine aminotransferase (ALT) ≤3 times ULN;
• Total bilirubin ≤2 times ULN (for patients with Gilbert's syndrome, total bilirubin ≤3.0 times ULN and direct bilirubin ≤1.5 times ULN);
• Serum creatinine ≤1.5 times ULN, or creatinine clearance ≥60 mL/min (using the Cockcroft-Gault formula);
• Left ventricular ejection fraction (LVEF) ≥50%;

Exclusion criteria

• Active infection at screening.
• Any of the following cardiac conditions:

• NYHA Class III or IV congestive heart failure;
• Severe arrhythmia requiring treatment;
• Uncontrolled hypertension or pulmonary hypertension despite standard therapy;
• Unstable angina;
• Myocardial infarction, bypass surgery, or stent placement within six months before cell retransfusion;
• Clinically significant valvular disease;
• Other cardiac conditions deemed unsuitable by the investigator;
• History of epilepsy, cerebellar disease, or other active central nervous system disorders;
• History of hypersensitivity to any component of the investigational product.
• Life expectancy of less than three months;
• Other conditions deemed unsuitable for participation in this clinical trial by the investigator.